Next, the transwell assay found that TY52156 markedly weakened the capacities of migration and invasion of TSC2-deficient cells, indicating that inhibition of S1PR3 reduced the metastatic capacity of tumor cells (Fig. 5F). Here, TSC2 is linked to neoplasm.